The reduction in price target by HC Wainwright & Co. could lead to a mixed short-term reaction in Mirum Pharmaceuticals' stock price. While the Buy rating reaffirms confidence in the company's prospects, the lowered price target may suggest a more conservative valuation or perceived near-term headwinds. Investors may weigh these factors differently, leading to neutral impact on the stock price in the short term.